CareDx, Inc.
CDNAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeCareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. Valued at $2.60B, CDNA is a mid-cap name in its sector. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Market Cap
$2.60B
Beta
2.43
P/E (TTM)
24.19
P/E (Fwd)
37.87
EPS (TTM)
$2.08
EPS (Fwd)
$1.33
ROE
29.5%
ROA
-0.3%
Cash
$373.6M
Total Debt
$19.2M
Free CF
$112.2M
52W Change
281.7%
Annual Financials
Cash vs Debt
Where CDNA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, CDNA finished 102.47% above its 150-day moving average ($25.86) and 117.71% above its 200-day moving average ($24.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDNA overbought or oversold?
At the August 28, 2026 close, CDNA's RSI(14) was 72.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $373.6M in cash comfortably exceeding the $19.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $112.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 29.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $321.8M to $379.8M.
CareDx, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CDNA.